INTRODUCTION
============

Although stroke is a rare event in childhood, it constitutes approximately 33% of all pediatric thrombosis cases \[[@ref1]\]. Stroke results in significant long-term morbidity and mortality in children. Various prothrombotic disorders, particularly those affecting the physiological anticoagulant system, are associated with the risk of stroke \[[@ref2]\]. Active protein C (APC) is a major natural anticoagulant that limits the progression of the coagulation cascade via photolytic degradation of factor Va (FVa) and factor VIIIa (FVIIIa). Endothelial protein C receptor (EPCR) contributes to the interaction between thrombin-thrombomodulin and PC, and in this way this complex increases activation of PC \[[@ref3]\].

PC activation is enhanced approximately 20-fold in vivo when PC is bound to EPCR \[[@ref4]\]. EPCR is not only a 46-kDa endothelial cell-specific type-I transmembrane protein, it also has a soluble form circulating in plasma \[[@ref5],[@ref6]\]. The extracellular domain of EPCR is cleaved with a metalloprotease and the cleavage results in the formation of soluble EPCR (sEPCR) \[[@ref7]\]. EPCR plays a role in regulating coagulation and inflammation. sEPCR binds to PC and APC with the same affinity as transmembrane EPCR \[8\]. Furthermore, sEPCR inhibits the anti-inflammatory, profibrinolytic, and anticoagulant effects of APC.

Elevated sEPCR is a risk factor for thrombosis \[[@ref9]\]. EPCR is primarily expressed in the endothelium of large blood vessel \[[@ref10]\]. EPCR is involved in numerous hemostatic, vascular, and immunological actions \[[@ref8],[@ref11],[@ref12],[@ref13]\]. To date, \>90 polymorphisms and 5 mutations of the human EPCR gene have been reported \[[@ref14],[@ref15],[@ref16]\]. The EPCR A3 haplotype in exon 4, rs867186 (p.ser219gly; A4600G) is associated with increased plasma levels of sEPCR and thrombosis \[[@ref17],[@ref18]\]. There is a strong association between the A3 haplotype and an elevated sEPCR level; an elevated sEPCR level might increase the risk of pediatric stroke \[[@ref12]\]. The aim of the present study was to investigate the EPCR gene A3 haplotype and plasma sEPCR level in Turkish pediatric arterial stroke patients.

MATERIALS AND METHODS
=====================

The study included 44 pediatric arterial stroke patients (20 girls 24 boys) and 75 healthy controls (51 girls and 24 boys) that had never had thrombosis. Patients with perinatal strokes were excluded. All of the patients in the patient group had arterial, large vessel stroke. The control and patient groups were selected from among the data in our DNA bank for the period 1998-2011. Mean age in the control group was 29.4 years (because of the contents of our DNA bank) and mean age in patient group is 5.57 years. The control group was selected from among a group aged \>18 years of age with no history of stroke.

Measurement of plasma sEPCR in the patient group was performed 6 months after the first episode of stroke. Pediatric stroke patients with neonatal onset were evaluated for sEPCR after the age of 1 year \[[@ref12]\]. Informed consent was obtained from the all the patients or their parents. The study protocol was approved by the Ethics Committee \[[@ref13]\]. sEPCR levels were measured via enzyme-linked immunosorbent assay (ELISA) (Diagnostica Stago Asserachrom sEPCR, Asnieres-France). sEPCR levels 38-132 ng µL--1 were accepted as normal, according to our laboratory's standards.

Genomic DNA was extracted and the frequency of the EPCR gene A3 haplotype 1651 C-G was screened via PCR using the primers 5^′^-GCTGAAATTTTGTATTCTGTCC-3^′^ and 5^′^-CCAGTATAATGGCTACATTTTACC-3^′^, and annealing at 54 ^°^C. C1651G substitution creates a Eco91 I restriction site. The 293-bp PCR products were incubated using Eco91 I restriction enzyme (Fermentas, Lithuania) at 37 ^°^C for 16 h, and then the digested products were electrophoresed on 3% agarose gel (Sigma, USA). Additionally, sequencing of this region of the gene was performed (Beckman Coulter CEQ 8000, Beckman Coulter, USA).

RESULTS
=======

The chi-square test, Student's t test, Fisher\'s exact test, and P values were used for statistical analysis. Comparison of continuous variables between the patients and controls was based on Student\'s t test. The relationship between sEPCR and the A3 haplotype was determined using both Pearson's and Spearman's rank correlation analysis. The chi-square test was used to compare the observed frequencies using the Hardy-Weinberg equilibrium prediction. Statistical significance was set at p\<0.05.

The frequency of the EPCR gene A3 haplotype (rs867186, C1651G, p.ser219gly) was determined ([Table 1](#t1){ref-type="table"}). There wasn't a significant difference in the sEPCR level between the controls (n=75; mean sEPCR: 110.3±68.0) and patients (n=44; mean sEPCR: 90.8±62.6) (p\> 0.05). In all, 34 of the pediatric arterial stroke patients carried 1651CC (mean sEPCR: 80.0±25.0), and 10 carried CG (CI = 0.67 \[0.2-1.6\]) and GG (CI = 4.7 \[0.18-119\]) (mean sEPCR: 213.3±67.5). There was a comparatively significant difference at the patient group in terms of their sEPCR levels and together with the A3 haplotype of the EPCR gene (p\<0.0001). Patients with the CG/GG genotype had higher plasma sEPCR levels than those with the CC genotype. Similarly, the mean sEPCR level in controls with the 1651CG/GG genotype (n=21; mean sEPCR: 60.1±28.8) was significantly higher than in those with 1651CC (n =54; mean sEPCR: 161.0±62.8) (p=0.000). Although there wasn't a significant difference in the distribution of the CC and CG/GG genotypes in the patient or control groups according to the chi-square test and Fisher's exact test (p\>0.05), the correlation between distribution of the sEPCR level and A3 haplotype, and the CC and CG/GG genotypes was significant (p= 0.01) based on Pearson's and Spearman's correlation analysis ([Table 1](#t1){ref-type="table"}).

DISCUSSION
==========

Several EPCR gene variations are accepted as risk factors for the development of thrombosis, because they cause a reduction in receptor expression or loss of receptor function. One such variation is a polymorphism referred to as haplotype 3. The EPCR A3 haplotype encodes serine instead of glycine at codon 219, which is located in the transmembrane region of EPCR \[[@ref19]\]. One study reported that among patients with venous thrombosis the incidence of this polymorphism was higher than in healthy individuals \[17\]. On the other hand, individuals carrying the homozygous A3 haplotype have a 3-fold greater risk of coronary heart disease \[[@ref18]\] and venous thrombosis \[9\]. The EPCR A3 haplotype is responsible for 86.5% of the variation in the sEPCR level that was generated via ADAM17 cleavage \[[@ref9],[@ref19]\].

In the present study there wasn't a significant difference in the sEPCR level between the control and patient groups, although the sEPCR level was higher in the patient group. Furthermore, CG/GG genotype carriers had higher plasma sEPCR levels than carriers of the CC genotype in both the patient and control groups. We did not observed a difference in the distribution of the CC and CG/GG genotypes between the control and patient groups. Further study on sEPCR levels at the onset of pediatric stroke is needed in order to reach a more definitive conclusion. As pediatric stroke is rare and its diagnosis at the onset of clinical symptoms is difficult, we think it would be beneficial to analyze sEPCR levels in adult stroke patients, as such data are lacking.
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###### Distribution of the A3 haplotype and the mean sEPCR level in the control and patient groups.

![](TJH-30-37-g1)
